GZR101 vs Insulin sudelidec (INS068)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
GZR101
Developed by Gan & Lee Pharmaceuticals
NCT06199505 · Phase 2 · completed
The study used randomization and an active comparator, but it was open-label and had a surrogate primary endpoint—change in HbA1c rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07387003 (registry estimate)
Reported efficacy
Change in HbA1c (Baseline to week 16): Change in HbA1c from baseline to week 16: Part A GZR101 once-daily -1.56% vs IDegAsp once-daily -1.31% (difference -0.24%); Part B GZR101+aspart once-daily -1.64% and twice-daily -1.68% vs IDegAsp twice-daily -1.59% (differences -0.06% and -0.09%). (met)
Result source: NCT06199505
Insulin sudelidec (INS068)
Marketed by Jiangsu Hengrui Pharmaceuticals
NCT05699408 · Phase 3 · completed
This Phase 3 trial randomly assigned 513 people with type 2 diabetes to insulin sudelidec or to insulin glargine, alongside their existing oral diabetes medicines. It was open-label, so treatment assignment was known throughout. HbA1c fell by 1.34 percentage points on insulin sudelidec against 1.37 on insulin glargine, a difference of 0.02 points (95% CI -0.14 to 0.18), meeting the prespecified test that it was not worse than glargine.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Change in HbA1c (Week 0 to Week 26): Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%) (met)
Result source: NCT05699408
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | GZR101 | Insulin sudelidec (INS068) |
|---|---|---|
| HbA1c, change | -1.6% vs -1.3%avs IDegAsp once-dailyNCT061995052 other results
| -1.3% vs -1.4%avs insulin glargineNCT05699408 |
| Body weight, change (kg) | —Not reported | —Not posted · NCT05699408 |
| HbA1c below 7% | —Not reported | —Not posted · NCT05699408 |
| Fasting plasma glucose, change | —Not reported | —Not posted · NCT05699408 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05699408 |
HbA1c, change
- GZR101
- -1.6% vs -1.3%avs IDegAsp once-dailyNCT06199505
2 other results
- -1.6% vs -1.6% NCT06199505
- -1.7% vs -1.6% NCT06199505
- Insulin sudelidec (INS068)
- -1.3% vs -1.4%avs insulin glargineNCT05699408
Body weight, change (kg)
- GZR101
- —Not reported
- Insulin sudelidec (INS068)
- —Not posted · NCT05699408
HbA1c below 7%
- GZR101
- —Not reported
- Insulin sudelidec (INS068)
- —Not posted · NCT05699408
Fasting plasma glucose, change
- GZR101
- —Not reported
- Insulin sudelidec (INS068)
- —Not posted · NCT05699408
3-point MACE (% with event)
- GZR101
- —Not reported
- Insulin sudelidec (INS068)
- —Not posted · NCT05699408
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR101's landscape · Insulin sudelidec (INS068)'s landscape